Characteristics | n | (%) |
---|---|---|
Number of total patients | 49 | |
Median age, years (range) | 43 (27–60) | |
Menopausal status | ||
Premenopause | 42 | (85.7%) |
Postmenopause | 7 | (14.3%) |
Histology | ||
Invasive ductal carcinoma | 46 | (93.9%) |
Invasive lobular carcinoma | 1 | (2.0%) |
Mixed type (ductal + lobular) | 2 | (4.1%) |
ECOG performance status | ||
0 | 25 | (51.0%) |
1 | 24 | (49.0%) |
Prechemotherapy T stage | ||
cT1 | 5 | (10.3%) |
cT2 | 37 | (75.5%) |
cT3 | 6 | (12.2%) |
cT4 | 1 | (2.0%) |
Prechemotherapy N stage | ||
cN0 | 0 | (0.0%) |
cN1 | 30 | (61.2%) |
cN2 | 14 | (28.6%) |
cN3 | 5 | (10.2%) |
AJCC clinical stage | ||
IIA | 3 | (6.1%) |
IIB | 25 | (51.0%) |
IIIA | 16 | (32.7%) |
IIIB | 0 | (0.0%) |
IIIC | 5 | (10.2%) |
Median tumor size by palpation, cm (range) | 4.0 (0–11.0) | |
Hormonal receptor status* | ||
Positive for ER or PgR | 36 | (73.5%) |
Negative for ER and PgR | 13 | (26.5%) |
HER2 status | ||
Positive | 0 | (0.0%) |
Negative | 49 | (100%) |